Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (1488)	3/1/1998 12:59:00 PM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

Sigmund, Things have been quiet. The tone of the thread was getting to be less than expected for a forum of this caliber. Obviously everyone was concerned about the sudden transition that had occurred, yet I think the quiet period was better for this thread than the direction that it was heading. Some additional news that we are to expect this month should include the Detroit Lab Study documenting the cost containment figures they realized by employing the AcCell System. This should prove favorable as it "piggy-backs" the internal figures published by AccuMed last week. Also the impact of the Blue Cross Blue Shield Research has yet to be fully realized. I do believe that the earnings release for the previous quarter will be timed with a balancing piece of favorable news. I think it might be an announcement of a "penned deal" contract for the old Olympus inventory. An upcoming analyst conference call is expected soon. I presume it will be laden with exact navigational coordinates for the immediate and longer term future of Company, the Sakura Joint Venture, etc. Doesn't the C stand for Chicago? <g>